Dosage form :
    PBX class :
    Active substance :
    Consist :

    1 tablet contains Clopidogrel 75 mg

    Dosage and Administration :

    Adults and elderly: Clopidogrel should be given as a single daily dose of 75 mg.

    In patients suffering from acute coronary syndrome:

    Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q wave myocardial infarction): clopidogrel treatment should be initiated with a single 300-mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily). Since higher doses of ASA were associated with higher bleeding risk it is recommended that the dose of ASA should not be higher than 100 mg.

    The optimal duration of treatment has not been formally established.

    Clinical trial data support use up to 12 months, and the maximum benefit was seen at 3 months.

    ST segment elevation acute myocardial infarction: clopidogrel should be given as a single daily dose of 75 mg initiated with a 300-mg loading dose in combination with ASA and with or without thrombolytics. For patients over 75 years of age clopidogrel should be initiated without a loading dose. Combined therapy should be started as early as possible after symptoms start and continued for at least four weeks. The benefit of the combination of clopidogrel with ASA beyond four weeks has not been studied in this setting.

    In patients with atrial fibrillation, clopidogrel should be given as a single daily dose of 75 mg. ASA(75-100 mg daily) should be initiated and continued in


    combination with Clopidogrel.

    If a dose is missed:

    Within less than 12 hours after regular scheduled time: patients should take the dose immediately and then take the next dose at the regular scheduled time.

    For more than 12 hours: patients should take the next dose at the regular scheduled time and should not double the dose.

    Indications for use:
    Clopidogrel tablets are indicated for the prevention of atherothrombotic events in patients suffering from myocardial infarction, ischaemic stroke or established peripheral arterial disease, acute coronary syndrome, also for the prevention of atherothrombotic and thromboembolic events in atrial fibrillation.